Recursion completes Phase 1 study for REC-3964; drug well tolerated, Phase 2 planned for 2024

RECURSION PHARMACEUTICALS, INC.

Phase 1 study of REC-3964 in healthy volunteers completed; no serious adverse events reported.
42 participants in MAD part; doses up to 900 mg for 14 days; PK dose-proportional, half-life 7-10 hrs.
Treatment-related AEs in 11.8% (4/34) of REC-3964 recipients, all mild; no discontinuations.
Phase 2 proof-of-concept trial in recurrent C. diff infection expected to start in 2024.
REC-3964 is novel non-antibiotic small molecule inhibitor of C. diff toxins; >730k cases US/EU5 annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.